Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of SGLT2i in noHCM With HFpEF
Sponsor: China National Center for Cardiovascular Diseases
Summary
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.
Official title: Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
94
Start Date
2022-08-01
Completion Date
2025-08-01
Last Updated
2024-05-06
Healthy Volunteers
No
Interventions
Empagliflozin 10 MG
Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
Locations (1)
Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China